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ABSTRACT
Chronic inflammation promotes breast tumor growth and invasion by accelerating angiogenesis and
tissue remodeling in the tumor microenvironment. There is a complex relationship between inflammation
and estrogen, which drives the growth of 70 percent of breast tumors. While low levels of estrogen
exposure stimulate macrophages and other inflammatory cell populations, very high levels are immune
suppressive. Breast tumor incidence is increased by obesity and age, which interact to influence
inflammatory cell populations in normal breast tissue. To characterize the impact of these factors on
tumors and the tumor microenvironment, we measured gene expression in 195 breast adenocarcinomas
and matched adjacent normal breast tissue samples collected at Akershus University Hospital (AHUS). Age
and Body Mass Index (BMI) were independently associated with inflammation in adjacent normal tissue
but not tumors. Estrogen Receptor (ER)-negative tumors had elevated macrophage expression compared
with matched normal tissue, but ER-positive tumors showed an unexpected decrease in macrophage
expression. We found an inverse relationship between the increase in tumor estrogen pathway expression
compared with adjacent normal tissue and tumor macrophage score. We validated this finding in 126
breast tumor-normal pairs from the previously published METABRIC cohort. We developed a novel
statistic, the Rewiring Coefficient, to quantify the rewiring of gene co-expression networks at the level of
individual genes. Differential correlation analysis demonstrated distinct pathways were rewired during
tumorigenesis. Our data support an immune suppressive effect of high doses of estrogen signaling in
breast tumor microenvironment, suggesting that this effect contributes to the greater presence of
prognostic and therapeutically relevant immune cells in ER-negative tumors.
Abbreviations: BMI, Body Mass Index; CTL, Cytotoxic Lymphocyte; ER, Estrogen Receptor; FDR, False Discovery Rate;
RC, Rewiring Coefficient; TAM, Tumor Associated Macrophages
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Introduction
Increasing age affects breast cancer predisposition and develop-
ment in complex ways. During the last century, epidemiologists
noted that the slope of the breast cancer incidence curve shifts at
approximately the age of menopause, and theorized that there
were 2 distinct forms of breast cancer distinguished by the activ-
ity of hormones.1,2 It is now known that breast tumors arising
after menopause more frequently respond to mitogenic signal-
ing through the estrogen receptor, and a woman’s lifetime risk
for breast cancer is correlated with her total estrogen exposure.3
Circulating 17b-estradiol is a hormone primarily produced in
the ovaries, but organs including the skin and breast can metab-
olize estrogen independently of the ovaries.4 Estrogen has wide-
ranging and complex effects on normal human physiology that
change during sexual maturation, pregnancy, and menopause.
Its most important and visible effects involve crucial roles in
development and functioning of the post-natal female reproduc-
tive system. Circulating estrogen levels are highest in the pre-
ovulatory phase of the menstrual cycle and during pregnancy
and decrease precipitously post-menopause,5 which typically
occurs around age 50. Breast tumors have aromatase activity
and can produce estrogen even after circulating estrogen levels
have dropped to very low levels.6
The response of macrophages and other inflammatory cell
populations to estrogen stimulation depends on both the dose
and the tissue context [reviewed in7]. Moderate levels of
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estrogen increase the pro-angiogenic activity of inflammatory
cells. However, estrogen exposure at levels found during preg-
nancy decreases cytokine production and suppresses the activ-
ity of inflammatory pathways such as NFKB.8-13 During
pregnancy, women with immune and inflammatory disorders
such as rheumatoid arthritis often experience temporary relief
of their symptoms.14 Topical estrogen has been shown to
improve epithelial wound healing in vivo by reducing the mac-
rophage response.15 There is therefore abundant evidence in
vivo that elevated estrogen exposure can have immune suppres-
sive and anti-inflammatory effects. The role of estrogen in
inflammatory responses is particularly relevant to breast can-
cer, as the tumor microenvironment of breast cancer is heavily
influenced by the tumor-promoting effects of tumor-associated
macrophages (TAM).16
Tumorigenesis results in dramatic changes in the overall lev-
els of gene expression compared with normal tissue, in part due
to changes in the proportions of different cell populations and
deregulated growth signaling. However, not all important sig-
naling and morphological changes can be detected by compar-
ing gene expression levels. Differential correlation and
differential network analysis have been previously proposed as
methods to identify how relationships between genes or pro-
teins change.17 Some methods determine whether pre-specified
gene sets are differently correlated in 2 conditions,18,19 while
others discover gene sets directly from the data.20 We devel-
oped a new gene-level differential correlation summary statistic
called the Rewiring Coefficient (RC) and use this approach to
dissect the effect of tumorigenesis on both gene expression lev-
els and relationships between genes.
The present study compared gene expression profiles of
breast adenocarcinomas to matched adjacent normal tissue and
tissue from disease-free women to characterize how gene net-
works affecting estrogen, basal keratins, and the tumor micro-
environment are altered by tumorigenesis. Our observations
suggest that the degree of prognostic and therapeutically rele-
vant immune cells in ER-negative tumors is linked inversely to
increases in estrogen signaling.
Results
Inflammation expression was elevated in adjacent normal
tissue
We measured gene expression in 195 breast adenocarcinomas
paired with adjacent normal tissue taken from the ipsilateral
breast, for a total of 390 samples. Patient age, BMI, and immuno-
histochemical tumor types of these patients are summarized in
Table 1. We also measured gene expression in breast tissue from
43 disease-free samples donated by healthy women undergoing
mammaplastic reduction surgery. We first explored how the
presence of a tumor altered the gene expression profile of nearby
pathologically normal tissue, using mammaplastic reduction
samples as controls. Principle component analysis of the entire
data set indicated that adjacent normal and mammaplastic
reduction samples were much more similar to each other than
to tumor samples (Fig. S1). Comparison of reduction mamma-
plasty tissue to adjacent normal and tumor tissue identified
7,505 and 11,173 differentially expressed genes, respectively;
comparison of comparing adjacent normal tissue to tumor tissue
identified 12,590 genes to be differentially expressed. We exam-
ined markers of adipocytes, basal keratins, and the extracellular
matrix, 3 of the key cell populations that make up breast tissue.
Expression levels of the adipocyte-derived hormone adiponectin
(ADIPOQ), the basal keratinocyte marker keratin 5 (KRT5), and
the extracellular matrix adhesion protein fibronectin (FN1) were
not significantly different between mammaplastic reduction and
adjacent normal samples (Fig. 1a). In both non-malignant sam-
ple types, expression levels of basal and adipose genes were
inversely correlated, a relationship that was abolished in tumors
(Fig. 1b). Similarly, expression of basal and luminal keratin
markers were directly correlated in non-malignant samples, but
this correlation was abolished in tumors (Fig. 1b). These results
were compatible with non-malignant samples having compara-
ble proportions and quantities of adipocytes, keratinocytes, and
matrix cells (Fig. 1a).
In contrast to expression of epithelial, matrix, and adipose
markers, adjacent normal tissue had significantly elevated
expression of cytokines associated with the acute inflammatory
response, such as interleukin 1B (IL1B), tumor necrosis factor
(TNF), and suppressor of cytokine signaling 3 (SOCS3), when
compared with mammaplastic reduction samples (Fig. 1c).
Expression of markers specifically associated with macro-
phages, such as myeloid cell nuclear differentiation antigen
(MNDA) and markers of dendritic cells, such as CD83, were
also elevated in adjacent normal tissue (Fig. 1d). Although the
tissue adjacent to the tumor was pathologically benign and sim-
ilar to disease-free breast tissue in its overall expression profile,
it demonstrated expression features associated with elevated
levels of cytokine activity and immune cell populations that
respond to those cytokine signals when compared with mam-
maplastic reduction samples.
Age and BMI are independently associated with
lymphocyte and macrophage expression in normal tissue
Breast cancer incidence increases with age due to a combina-
tion of age-related physiologic changes, exposure to environ-
mental carcinogens, and random DNA mutations. Aging is
also associated with decreased adaptive immune efficacy and
increases in circulating monocytes.21-23 Patient age was signifi-
cantly correlated with the expression of 53 genes in adjacent
normal tissues (P < 0.05, Holm’s correction, Supplementary
Table 3). This gene list was significantly enriched for genes
important in the inflammatory response and positive regulation
Table 1. Clinical summary of AHUS patients.
ERC HER2- HER2C ER- HER2- total
BMI
Normal ( 25) 52 18 16 86
Overweight (25–30) 34 8 8 50
Obese ( 30) 20 3 3 26
NA 29 3 1 33
Total 135 32 28 195
Age group
Early ( 50) 30 7 11 48
Middle (50–70) 65 17 9 91
Late ( 70) 40 8 8 56
Total 135 32 28 195
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Figure 1. Adjacent normal tissue has an elevated acute inflammatory response (a) Box plots of gene expression for the adipose marker ADIPOQ, basal keratin 5 (KRT5), and
extracellular matrix protein fibronectin 1 (FN1) in mammaplastic reduction (mam. red.), adjacent normal (adj. normal), and tumor tissue. All 3 genes show similar expres-
sion levels in levels in adjacent normal and mammaplastic reduction samples. (b) Scatter plots of expression of ADIPOQ vs. KRT5 and KRT8 vs. KRT5 show correlation rela-
tionships are consistent in normal adjacent and mammaplastic reduction tissue but disrupted in tumors. (c) Box plots of early response cytokines interleukin 1 b (IL1B),
tumor necrosis factor (TNF) and suppressor of cytokine signaling 3 (SOCS3) show elevated expression in adjacent normal tissue, as do (d) box plots of the macrophage
marker myeloid cell nuclear differentiation antigen (MNDA) and the dendritic cell marker CD83. (e) Scatter plots of age vs. expression of MSR1, GZMA, and CD247, and of
BMI vs. ADIPOQ, LEP, and MSR1, all in adjacent normal tissue. All plots show statistically significant positive correlations except BMI vs. ADIPOQ.
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of T cell activation, such as the Macrophage Scavenger Recep-
tor (MSR1), the cytolytic Granzyme A (GZMA), and the T cell
receptor zeta (CD247) (Fig. 1e). We summarized macrophage
and cytotoxic lymphocyte (CTL) gene expression as pathway
expression scores (Methods) and found that the scores were
significantly associated with age in adjacent normal tissue
(Macrophage score rho D 0.25, P D 0.0004; CTL score
rho D 0.19, P D 0.007, Fig. S2) but not in tumors.
Obesity has been associated with increased macrophage
infiltration in adipose tissue, including in normal breast
tissue,24-26 and with increased breast tumor incidence in
post-menopausal women.27,28 In the AHUS patients, BMI
was not significantly associated with age or tumor subtype.
Expression of markers of adipocytes such as ADIPOQ was
not significantly correlated with patient BMI in adjacent nor-
mal tissue, but BMI was significantly associated with expres-
sion of leptin (LEP), a hormone secreted in adipose tissue
whose levels are associated with BMI29 (Fig. 1e). BMI was
also significantly associated with MSR1 expression (Fig. 1e)
and with macrophage pathway expression levels in adjacent
normal tissue (BMI vs. macrophage adjusted rho D 0.48,
P D 8 £ 10¡11, Fig. S3) but not in tumors. The fact that
both age and BMI were positively associated with levels of
inflammatory cell expression in non-malignant tissue is con-
sistent with a model where these factors affect the microenvi-
ronment in which the tumor forms.
Later-onset ER-positive tumors have elevated expression
of ESR1 mRNA and protein
It is unknown what tumor intrinsic or extrinsic factors may
predispose the development of particular breast tumor sub-
types. We attempted to identify associations between tumor
subtype and gene expression in adjacent normal tissue. Con-
sidering all 195 patients together, no gene was significantly
differentially expressed in adjacent normal tissue from
patients with ER-positive tumors compared with that of
patients with ER-negative tumors, and no gene pair was sig-
nificantly differentially correlated between these groups. We
next performed an analysis stratified by patient age, catego-
rizing patients into early, middle, and late disease onset age
groups (<50 years, 50 to 70 years, and >70 y respectively).
We chose 50 y because it is the average age of the onset of
menopause. We summarized gene expression levels of key
genes and pathways in normal and tumor tissue grouped by
age and immunohistochemical subtype, plotting the median
expression in the gene or pathway standardized against its
expression in mammaplastic reduction samples as a baseline
(Fig. 2a). Performing differential expression analysis within
each age group revealed that 3,980 genes were significantly
differentially expressed in the adjacent normal tissue of
women with early-onset disease when stratified by the ER
status of their tumors (Supplementary Table 4).
The expression level of estrogen receptor a (ESR1) in adja-
cent normal tissue was not significantly associated with age of
disease onset or tumor ER status (Fig. 2a, Fig. S4). However,
women with early-onset ER-negative tumors had significantly
higher expression of estrogen response pathway genes, luminal,
and basal markers, and significantly lower expression of
markers of adipocytes in adjacent normal tissue (Fig. 2a,
Fig. S4). These differences were not simply the result of age-
related reductions in circulating hormone levels or decreases in
parenchymal density, as age-matched women with ER-positive
tumors did not show this expression phenotype. It was unlikely
that elevated hormone levels in normal tissue resulted from the
presence of elevated estrogen levels in nearby tumor tissue,
since this expression pattern was identified only in women with
ER-negative tumors. These differences were compatible with
early-onset ER-negative women possessing denser breast tissue,
which would result in a higher relative expression of epithelial
markers such as KRT5 and KRT8.
The largest significant differences in expression levels when
comparing adjacent normal tissue to tumors were increases in
expression of mitotic pathway genes and decreases in adipogene-
sis pathway genes (Fig. 2a). Women with later-onset ER-positive
tumors had significantly higher increases in the expression of
ESR1 compared with women with early-onset ER-positive tumors
(1.6-fold vs. 4.3-fold, P D 5 £ 10¡6, Wilcoxon rank sum test,
Fig. 2a). Constructing a linear model for change in ESR1 expres-
sion identified a modest but significant relationship between later
age of onset for ER-positive tumors and larger increases in ESR1
expression (rhoD 0.23, PD 0.005, Fig. 2b). This result confirmed
earlier studies performed by tissue microarray.30,31
We validated the association between older age and levels of
tumor ESR1 using mRNA from the METABRIC cohort (rho D
0.139, P< 2£ 10¡16, Fig. S5a).32 To rule out the possibility that
this effect was confounded by the larger proportion of Luminal
B tumors in older women compared with younger women, we
confirmed this effect was present within Luminal A METABRIC
tumors (Fig. S5b). This association was also found in protein
expression data from 408 breast tumors published by the TCGA
(rhoD 0.42, P D 9 £ 10¡15, Fig. S5c).33 These data emphasize
that age is an important covariate when assessing ESR1 mRNA
and protein expression levels in breast tumors.
Change in macrophage score varied inversely with change
in ESR1 expression in ER-positive tumors
We next performed a more detailed analysis of immune cell
gene expression. All types of tumors had significantly higher
CTL pathway scores compared with mammaplastic reduction
or adjacent normal tissue (Fig. 2a). CTL pathway scores were
highest in HER2-positive and ER-negative/HER2-negative
tumors. The difference in tumor CTL scores compared with
matched adjacent normal tissue was 2-fold higher in patients
with ER-negative tumors compared with patients with ER-posi-
tive tumors (Table 2). Unlike the CTL scores, macrophage
pathway scores were not significantly different between tumors
and adjacent normal tissue when considering all 195 patients.
However, when we stratified the analysis by tumor subtype, we
found that macrophage scores were significantly lower in ER-
positive, and in particular ER-positive/HER2-negative tumors,
than in matched adjacent normal tissue (Fig. 3a, Table 2).
To identify potential drivers of macrophage activity in ER-
positive tumors, we identified genes whose difference in expres-
sion was significantly correlated with the change in macro-
phage score. The change in macrophage pathway score was
inversely correlated with the change in ESR1 expression in ER-
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positive but not ER-negative patients (rho D ¡0.56, P < 2 £
10¡12, Fig. 3b). Women with the largest increase in ESR1
expression in their tumor compared with adjacent normal tis-
sue had the largest decrease in tumor macrophage pathway
score. We confirmed this finding in an independent cohort of
124 matched tumor and adjacent normal samples from the
METABRIC study (rho D ¡0.64, P < 7 £ 10¡13, Fig. 3c).
These results were compatible with increased estrogen in ER-
Figure 2. Expression of key genes and pathways in adjacent normal and tumor samples. (a) Relative expression of individual genes and pathways compared with 43 dis-
ease-free mammaplastic reduction tissue samples, grouped by age and hormone receptor status. Values were standardized by subtracting the corresponding median
value for in mammaplastic reduction samples and dividing by the standard deviation across groups. Darker blue indicates lower expression than the median expression
of all mammaplastic reduction, darker red indicates higher expression. (b) scatter plot of the fold-change in ESR1 expression plotted against patient age in ER-positive
HER2-negative AHUS patients with a linear regression line fitted, showing a significant direct correlation.
ONCOIMMUNOLOGY e1356142-5
positive tumors acting in an immune-suppressive manner on
macrophages, although other explanations cannot be ruled out
from these correlative observations.
Basal gene networks were rewired in ER-positive tumors
compared with adjacent normal tissue
We next combined correlation analysis and differential expres-
sion analysis to dissect how the pathways described above are
rewired during tumorigenesis. In normal breast ducts, luminal
and basal cells grow in a bilayer, and expression levels of lumi-
nal and basal keratins are highly correlated. Luminal and
estrogen-responsive genes such as GATA3 were strongly upre-
gulated in ER-positive tumors compared with adjacent normal
tissue (Fig. 2a). Correlation between expression of GATA3 and
basal genes such as KIT and KRT5 was significant in adjacent
normal tissue but not significant in ER-positive tumors
(Fig. 4a). In contrast to estrogen-driven and luminal markers,
basal genes such as KRT14, TRIM29, and PROM1 did not sig-
nificantly change expression levels in ER-positive tumors.
These genes lost correlation with the luminal and mesenchymal
pathways with which they were very strongly correlated in adja-
cent normal tissue (Fig. 4b). The loss of correlation without
changes in expression levels suggested an increase in the lumi-
nal but not the basal compartment of the tissue. Genes with
roles regulating cell migration, epithelial-mesenchymal interac-
tions, and epithelial differentiation such as Fibroblast growth
factor 7 (FGF7), an epithelial mitogen produced in mesenchy-
mal cells,34 tended to gain correlation but decrease in expres-
sion levels in tumors. FGF7 was expressed at 1.8-fold lower
levels in ER-positive tumors than in adjacent normal tissue, but
only in tumors was its expression inversely correlated with pro-
liferation and luminal markers, and only in tumors was its
expression directly correlated with that of other markers of epi-
thelial differentiation such as decorin, caveolin 1, and ZEB2
(Fig. 4c).
To analyze these trends in an unbiased, genome-wide man-
ner we developed a novel summary statistic, the Rewiring Coef-
ficient (RC). This statistic quantifes the extent to which each
gene’s expression relationships are altered between 2 states
(Methods). We then plotted each gene’s RC value against its
differential expression statistic to identify pathway alterations
(Fig. 4c). Highlighting the correlation and expression level
alterations of genes representing the basal, luminal, CTL, and
other pathways (Fig. 4d) illustrated several routes to deregula-
tion of homeostatic pathways: 1) higher expression and loss of
existing correlation networks (luminal, estrogen response, stro-
mal genes); 2) higher expression and gain of new correlation
networks (mitotic genes); 3) lower expression and gain of cor-
relation networks (macrophage genes); 4) no change in expres-
sion levels, and loss of correlation networks (basal genes). In
the case of the basal gene network, differential correlation iden-
tified a pathway alteration that would not have been identified
from differential expression analysis alone.
Discussion
This study compared gene expression in breast adenocarci-
nomas to gene expression in matched adjacent normal tis-
sue and tissue from women who underwent mammaplastic
reduction surgery. Both adjacent normal and mammaplastic
reduction tissues have been used as normal controls in
studies of breast tumors. Adjacent normal tissue has the
advantage that it is easily obtainable at the time of surgery
and is matched to tumor tissue in germline genotypes, age,
BMI, and other covariates. Adjacent normal tissue from
women with tumors had elevated expression of inflamma-
tory genes and a macrophage gene signature compared with
Figure 3. Stronger estrogen pathway expression in ER-positive tumors is associ-
ated with lower tumor inflammation (a) Macrophage pathway expression score in
paired adjacent normal (black points) and tumors (blue points) in ER-positive/
HER2-negative, ER-positive/HER2-positive, ER-negative/HER2-positive, and ER-neg-
ative/HER2-negative patients. Samples from the same patient are connected by a
vertical line. The majority of ER-positive tumors express lower levels of macro-
phage markers than their matched adjacent normal tissue. (b,c) Fold-change in
expression of ESR1 plotted against fold-change in macrophage score in ER-positive
HER2-negative (b) AHUS and (c) METABRIC samples, demonstrating a significant
inverse linear relationship.
Table 2. Difference in paired macrophage and CTL scores by tumor subtype.
score type ER HER2
mean paired
difference
95% CI
for mean P value
macrophage positive any ¡0.49 ¡0.64 to ¡0.34 8 £ 10¡10
macrophage negative any 0.42 0.10 to 0.73 1 £ 10¡2
macrophage positive negative ¡0.48 ¡0.64 to ¡0.33 2 £ 10¡8
macrophage positive positive ¡0.57 ¡1.07 to ¡0.07 2 £ 10¡2
macrophage negative positive 0.64 0.20 to 1.08 8 £ 10¡3
macrophage negative negative 0.29 ¡0.14 to 0.73 0.18
CTL positive any 0.54 0.40 to 0.68 1 £ 10¡12
CTL negative any 1.06 0.78 to 1.33 2 £ 10¡9
CTL positive negative 0.53 0.39 to 0.68 2 £ 10¡11
CTL positive positive 0.59 0.10 to 1.10 2 £ 10¡2
CTL negative positive 0.95 0.54 to 1.34 2 £ 10¡3
CTL negative negative 1.10 0.73 to 1.50 3 £ 10¡6
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Figure 4. Gene expression network rewiring in ER-positive tumors (a-c) Heat maps of standardized gene expression for genes significantly differentially correlated with (a)
GATA3 (b) KRT14 and (c) FGF7 in matched adjacent normal and ER-positive tumors, sorted by GATA3, KRT14, and FGF7 expression respectively. The condition where the
target gene was significantly correlated with the other genes in each plot is indicated (all P < 1 £ 10¡17). Correlation measurements are listed
in Table S5. (d-e) Scatter plot of Rewiring Coefficient (RC) analysis of gene expression in adjacent normal compared with matched ER-positive tumors, with RC for each
gene plotted on the X axis and the t statistic for difference in means plotted on the Y axis. Genes with significant differential correlation (P < 0.05 after Holm’s correction)
plotted as round points; non-significant genes plotted as open triangles. Point color indicates whether correlation was stronger in tumors (darker red) or adjacent normal
tissue (darker blue). (e) RC analysis using plotted using data from (d), showing representative pathway members listed in Table S6.
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samples from mammaplastic reduction surgery, arguing that
while these samples are a valuable source of information
about the milieu in which the tumor formed, they are not
truly normal. Breast adenocarcinomas are initiated in lumi-
nal ductal or lobular cells, but the tumors are a product of
both the initiated epithelium and the stroma that surrounds
and pervades that epithelium. Expression analysis of breast
tumor stroma has been shown to have predictive power for
clinical outcome,35,36 evidence of cross-talk between the
tumor and adjacent non-malignant tissue. The tumor
microenvironment is a complex mix of structural, inflam-
matory, and immune cells.37-40
Differences in patient age and BMI between breast cancer
patients and mammaplastic reduction patients complicate the
interpretation of this study.
One potential disadvantage of using samples from mam-
maplastic reduction surgery as true normal controls is that
these patients are on average 20 y younger than women with
non-familial breast cancer, and are more likely to be over-
weight or obese.41 Women generally undergo mammaplastic
reduction surgery before the average age of breast cancer
onset, and we showed that increasing age had a modest but
significant influence on macrophage gene expression scores.
However, increased BMI also had a significant influence on
macrophage gene expression scores, so it is not obvious to
what extent or direction controls from younger women with
higher BMI would be confounded when compared with older
cases with a range of BMI scores. A previous report compar-
ing gene expression in mammaplastic reduction and adjacent
normal samples did not identify a statistically significant dif-
ference in expression levels.42 In that study Finak et al. ana-
lyzed microdissected samples from a smaller number of
individuals than the present report (adjacent normal tissue
from 34 patients with invasive ductal carcinoma and 10
patients undergoing reduction). Microdissection provides
targeted insights into the physiology of specific cell compart-
ments, which is complementary analysis to whole-tissue
samples, which have the potential to provide information
about the relationship between epithelial and immune cells
in the tumor microenvironment.
The use of BMI as a surrogate measure of obesity has been
criticized because BMI does not distinguish between mass
due to fat vs. mass due to lean tissue such as muscle.43
Although BMI is an imperfect measure of obesity, BMI has
been shown to be an meaningful proxy for direct measure-
ment of obesity in studies of female sex hormone concentra-
tion,44 and meta-analysis of large-scale population studies
has shown elevated BMI is associated with increased post-
menopausal breast cancer risk,45,46 and increased weight is
linked to increased quantities of available circulating estro-
gen.27,28 Excess android (abdominal and upper-body) adipose
accumulation is also associated with increased levels of
inflammatory activity driven by macrophages resident in
adipose tissue.24,26,47 Our analysis identified age- and BMI-
associated increases in inflammation and suggested that these
effects act independently and additively (summarized in
Fig. 5a). Although BMI may also influence macrophage infil-
tration into tumors, we did not observe a direct association
between BMI and macrophage score in any subtype of tumor.
This is compatible with the primary effect of BMI on breast
cancer susceptibility acting indirectly on inflammation and
estradiol production in the tumor microenvironment rather
than within the tumor itself. This result was consistent with
the finding presented above that BMI was strongly associated
with elevated macrophage expression score in all adjacent
normal tissue samples. It may be that women with higher
BMI have smaller increases in their macrophage expression
score because of the microenvironment surrounding their
tumors already had an elevated presence of macrophages.
ER-negative tumors tend to be larger, of higher grade, and
with more developed vascular infrastructure than ER-positive
tumors. ER-negative, Basal-like tumors have been associated
with elevated expression of a Colony Stimulating Factor 1
(CSF1) expression signature,48,49 reviewed in.50 The present
study found that tumors from women with ER-negative disease
had elevated expression of macrophage pathways compared
with matched adjacent normal tissue. In contrast, we found
that in women with ER-positive tumors, there was an overall
decrease in macrophage pathway expression, and that the
larger the increase in ESR1 expression in the tumor compared
with adjacent normal tissue, the lower the macrophage expres-
sion score (Fig. 5a).
This study did not directly quantify either the amount of
estradiol in tumors and adjacent normal tissue or the num-
ber of infiltrating macrophages in tumors. These data are
compatible with an inverse correlation between macrophage
activity and estrogen exposure in ER-positive but not ER-
negative tumors, which could be explained by the anti-
inflammatory effects of estrogen which have been exten-
sively described.7 However, we cannot rule out the opposite
effect: that reduced macrophage infiltration in ER-positive
tumors causes larger production of ESR1 and other genes in
the estrogen response pathway. Estradiol and cytokine pro-
duction in the tumor and tumor microenvironment likely
influence each other both positively and negatively.
Figure 5. Summary of age, BMI, and differential correlation results (a) BMI and age
independently increase inflammation in adjacent normal tissue (arrow). Older age
is associated with larger increases in ESR1 expression in tumors (arrow). Larger
increases in estrogen levels from adjacent normal to tumor are inversely associated
with tumor macrophage scores (dotted line). (b,c) Differential correlation pathway
summary, where solid lines indicate direct correlation and dotted lines indicate
inverse correlation in either (b) adjacent normal or (c) ER-positive tumors. Node
color indicates relative expression levels compared with adjacent normal (gray),
where red indicates increased and blue indicates decreased expression. Individual
genes emblematic of the pathway are noted on the figure.
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Macrophages in the breast can contribute to estrogen pro-
duction in situ,51,52 and macrophage and lymphocyte syn-
thesis of cytokines may be a major source of estradiol in
breast tumors.53 The presence in tumors of infiltrating cyto-
toxic T cells is significantly associated with better survival
in ER-negative but not ER-positive breast tumors.54
This study used differential correlation analysis to illus-
trate major pathway and cell composition alterations that
occur during the transition from normal tissue to ER-posi-
tive breast cancer (summarized in Fig. 5b, 5c). We defined
the Rewiring Coefficient, method that characterizes the
extent to which a gene’s relationship to the rest of
the genome is altered between 2 states. ER-positive tumors
are sometimes characterized as expressing lower levels of
canonical basal markers such as KRT5 and EGFR. We
found that while markers of luminal gene expression such
as KRT8 were expressed at higher levels in ER-positive
tumors compared with matched adjacent normal tissue,
basal marker expression remained constant. Differential
correlation analysis indicated that despite similar levels of
expression, there was a profound rewiring of the relation-
ship between basal keratins, luminal keratins, and the estro-
gen response pathway.
This study provides evidence that the association of the lev-
els of both adaptive and innate immune cells in breast tumors
with ER status may be directly linked to the anti-inflammatory
and anti-immune effects of estrogen. Elevated BMI was associ-
ated with molecular markers of inflammation in normal tissue
but not tumors. The Rewiring Coefficient method has the
potential to identify different cell populations and deregulated
growth signaling and may be useful in studies of tumor
heterogeneity.
Materials and methods
Statistical methods
Statistical calculations were performed in the R statistical pro-
gramming environment.55 Where adjusted r2 is reported, the
test performed was a linear regression. Spearman rank correla-
tion rho was reported for correlation analysis. Interaction was
tested by ANOVA. Differential expression was calculating
using Significance Analysis of Microarrays56 with significant
differences assessed at a 5% False Discovery Rate. Correlation
between age or BMI and gene expression was corrected for
multiple testing using Holm’s method. Pathway enrichment
was calculated using BiNGO57 with P values corrected by Ben-
jamini & Hochberg’s FDR method. Values in Table 2 were cal-
culated by paired t test. Gene signatures were downloaded from
MSigDB version 4.058 Macrophage pathway genes were selected
calculating correlation between expression of CD14, CD11B,
and CD163 and all other genes in all AHUS samples, identify-
ing the top 100 genes from each of the 3 calculations, and then
selecting those genes which appeared on the intersection of all
3 lists. Basal and Luminal pathway genes were selected as the
40 genes whose expression was most significantly correlated
with expression of KRT5 and KRT8 respectively. The gene com-
position of all signatures used in this manuscript is listed in
Supplementary Table 1. METABRIC gene expression data were
downloaded from the European Genome-Phenome Archive,
accession EGAS00000000083. TCGA protein expression data
were downloaded from the TCGA data portal (https://tcga-
data.nci.nih.gov/tcga). R code to reproduce the microarray nor-
malization and the complete analysis can be downloaded from
http://davidquigley.com/publications.
Rewiring coefficient analysis
Fisher’s Z transformation converts Pearson’s r or Spearman’s
rho to a normally distributed z0 value with standard error (se)
described as:
z
0 D 1
2
ln
1C rho
1¡ rho
 
; se D
ffiffiffiffiffiffiffiffiffiffi
1
n¡ 3
r
where n is the number of elements. The difference of 2 z0 val-
ues, zdiff, is approximately standard normally distributed and is
calculated as:
Zdiff D Z
0
1 ¡Z 02
se1¡ se2
The Rewiring Coefficient (RC) for a gene is the sum of zdiff
scores for differential correlation between a gene and all other
genes under consideration, normalized by the number of genes.
For N genes g1..N the RC for gene i is:
RCiD
PN
jD 0
j 6¼ i
hzdiff gi; gj 
i
N
RC significance was calculated by permutation testing,
which randomly shuffled class assignments and generated
empirical permutation P values for each gene. False Discov-
ery Rate estimation was then performed using the qvalue
package in R. We implemented the RC calculation in an
open-source CCC software package called spear, which also
calculates correlation and differential correlation. The spear
program is multi-threaded and can natively exploit multi-
core cluster environments. spear source code and executable
code is freely available at http://github.com/davidquigley/
QuantitativeGenetics.
Patient population
The 195 breast cancer patients in this study (the AHUS cohort)
were seen at the Akershus hospital in Norway during the last
10 y. BMI was available for 162 patients and ranged from 16.9 to
46.8, with a median of 24.8. Forty-seven percent of the patients
had a BMI above 25 and 16% had a BMI above 30, frequently
used standards for overweight and obesity. AHUS patient’s ages
at the time of surgery ranged from 31 to 96 years, with a median
value of 61.2 y. This study was approved by REC SouthEast
(Regional Ethical Committee for Medical and Health Research
Ethics) and by the Ethical Committee for Aarhus county and by
“Datatilsynet” (The Data Inspectorate, an independent
ONCOIMMUNOLOGY e1356142-9
administrative body under the Ministry of Government Admin-
istration and Reform). All patients gave consent to the use of
material for research purposes in adherence with the Declara-
tion of Helsinki Principles. Supplementary Table 2 provides
clinical characterization for all subjects including BMI, age, and
tumor staging.
Sample preparation
Tissue samples were stabilized with RNAlater at the time of sur-
gery. After surgery, RNAlater was removed and tissue was stored
at¡80C. RNA was extracted with TRIzol (Invitrogen, Carlsbad
CA) or TRI reagent (Life Technologies, Gaithersburg MD) and
further purified on RNeasy columns in combination with the
RNeasy Mini Kit (Qiagen, Valenca, CA). RNA was quantified
using a NanoDrop ND-1000 spectrophotometer (Thermo Sci-
entific, Wilmington DE) and quality checked with an Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
mRNA expression levels were measured using the Agilent Tech-
nologies Agilent-014850 Whole Human Genome Microarray 4
£ 44K and the Agilent G4851A SurePrint G3 Human Gene
Expression 8£ 60Kmicroarray platforms scanned by an Agilent
scanner (Agilent Technologies, Santa Clara USA). Raw microar-
ray data were quantile normalized using the limma package in
R.59 Missing values were imputed using the impute package in R.
Individual probes were re-annotated by aligning published
probe sequences to human reference sequence HG19 using
BLAT.60 Platforms were combined by collapsing all probes
annotated to a single gene into one value. To combine multiple
probes for one gene into a single value we used the mean of mul-
tiple probes annotated to match a single gene if they were corre-
lated at rho  0.8; if no pair of probes was correlated at rho 
0.8, the probe with the highest variance was used. Platforms
were then batch corrected using ComBat.61 14,637 genes were
expressed above background levels.
Data availability
Microarray data can be accessed from the GEO database,
(http://www.ncbi.nlm.nih.gov/geo) with accession number
GSE70951.
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